Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UFM1-specific ligase 1 (UFL1) is the sole known E3 ligase responsible for catalyzing UFM1 (ubiquitin-fold modifier 1) conjugation (ufmylation) to protein substrates in eukaryotic cells, a process essential for regulating endoplasmic reticulum (ER) homeostasis, stress responses, hematopoiesis, and multiple other biological processes[1][2][3]. UFL1 forms a complex with adaptor proteins such as DDRGK1 and CDK5RAP3 to exert its E3 ligase activity, acting as a scaffold-type ligase, and is usually anchored on the cytoplasmic ER membrane[1][2][3]. UFL1 deficiency leads to complete loss of ufmylation, hematopoietic failure, and embryonic lethality in animal models, highlighting its essential role in cell survival and organ development, and connecting UFL1 to diseases such as cancer, inflammatory conditions, and ER-stress pathologies[1][3]. No drugs currently target UFL1 directly, but its unique and central role in the UFMylation pathway makes it a potential therapeutic target under investigation[1][3].
Scaffold for E2 (UFC1) and substrate recruitment to catalyze UFM1 transfer (protein ufmylation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UFM1-specific ligase 1 (UFL1).